First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

Didier Meulendijks; Wolfgang Jacob; Maria Martinez-Garcia; Alvaro Taus; Martijn P Lolkema; Emile E Voest; Marlies H G Langenberg; Tania Fleitas Kanonnikoff; Andres Cervantes; Maja J De Jonge; Stefan Sleijfer; Morten Mau-Sørensen; Marlene Thomas; Maurizio Ceppi; Georgina Meneses-Lorente; Ian James; Celine Adessi; Francesca Michielin; Keelara Abiraj; Birgit Bossenmaier; Jan H M Schellens; Martin Weisser; Ulrik Niels Lassen

doi:10.1158/1078-0432.ccr-15-1683

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

Didier Meulendijks, Wolfgang Jacob, Maria Martinez-Garcia, Alvaro Taus, Martijn P Lolkema, Emile E Voest, Marlies H G Langenberg, Tania Fleitas Kanonnikoff, Andres Cervantes, Maja J De Jonge, Stefan Sleijfer, Morten Mau-Sørensen, Marlene Thomas, Maurizio Ceppi, Georgina Meneses-Lorente, Ian James, Celine Adessi, Francesca Michielin, Keelara Abiraj, Birgit BossenmaierJan H M Schellens, Martin Weisser, Ulrik Niels Lassen

Department of Clinical Medicine

38 Citations (Scopus)

Abstract

PURPOSE: A first-in-human phase I study was conducted to characterize safety, efficacy, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of lumretuzumab, a humanized and glycoengineered anti-HER3 monoclonal antibody, in patients with advanced cancer.

EXPERIMENTAL DESIGN: Twenty-five patients with histologically confirmed HER3-expressing tumors received lumretuzumab (100, 200, 400, 800, 1,600, and 2,000 mg) every two weeks (q2w) in 3+3 dose-escalation phase. In addition, 22 patients were enrolled into an extension cohort at 2,000 mg q2w.

RESULTS: There were no dose-limiting toxicities. Common adverse events (any grade) included diarrhea (22 patients, 46.8%), fatigue (21 patients, 44.7%), decreased appetite (15 patients, 31.9%), infusion-related reactions (13 patients, 27.7%), and constipation (10 patients, 21.3%). The peak concentration (Cmax) and area under the concentration-time curve up to the last measurable concentration (AUClast) of lumretuzumab increased more than dose proportionally from 100 mg up to 400 mg. Linear PK was observed with doses ≥ 400 mg q2w indicating target-mediated drug disposition saturation. Downregulation of HER3 membranous protein was observed in on-treatment tumor biopsies from 200 mg, and was maximal at and above 400 mg. An ex vivo assay demonstrated increased activation potential of peripheral NK lymphocytes with lumretuzumab compared with a non-glycoengineered anti-HER3 antibody. Ten patients (21.3%) had stable disease and remained on study at a median of 111 days (range, 80-225 days).

CONCLUSIONS: Lumretuzumab was well tolerated and showed evidence of clinical activity. Linear serum PK properties and plateauing of PD effects in serial tumor biopsies indicate optimal biologically active doses of lumretuzumab from 400 mg onwards.

Original language	English
Journal	Clinical Cancer Research
Volume	22
Issue number	4
Pages (from-to)	877-85
Number of pages	9
ISSN	1078-0432
DOIs	https://doi.org/10.1158/1078-0432.ccr-15-1683
Publication status	Published - 15 Feb 2016

Keywords

Journal Article
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1078-0432.ccr-15-1683

877.full.pdfFinal published version, 986 KB
877.full.pdfFinal published version, 986 KB

https://clincancerres.aacrjournals.org/content/clincanres/22/4/877.full.pdf

Cite this

Meulendijks, D., Jacob, W., Martinez-Garcia, M., Taus, A., Lolkema, M. P., Voest, E. E., Langenberg, M. H. G., Fleitas Kanonnikoff, T., Cervantes, A., De Jonge, M. J., Sleijfer, S., Mau-Sørensen, M., Thomas, M., Ceppi, M., Meneses-Lorente, G., James, I., Adessi, C., Michielin, F., Abiraj, K., ... Lassen, U. N. (2016). First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors. Clinical Cancer Research, 22(4), 877-85. https://doi.org/10.1158/1078-0432.ccr-15-1683

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors. / Meulendijks, Didier; Jacob, Wolfgang; Martinez-Garcia, Maria et al.

In: Clinical Cancer Research, Vol. 22, No. 4, 15.02.2016, p. 877-85.

Research output: Contribution to journal › Journal article › Research › peer-review

Meulendijks, D, Jacob, W, Martinez-Garcia, M, Taus, A, Lolkema, MP, Voest, EE, Langenberg, MHG, Fleitas Kanonnikoff, T, Cervantes, A, De Jonge, MJ, Sleijfer, S, Mau-Sørensen, M, Thomas, M, Ceppi, M, Meneses-Lorente, G, James, I, Adessi, C, Michielin, F, Abiraj, K, Bossenmaier, B, Schellens, JHM, Weisser, M & Lassen, UN 2016, 'First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors', Clinical Cancer Research, vol. 22, no. 4, pp. 877-85. https://doi.org/10.1158/1078-0432.ccr-15-1683

@article{02f7815d476f4bfe9d8846c66a62d194,

title = "First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors",

abstract = "PURPOSE: A first-in-human phase I study was conducted to characterize safety, efficacy, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of lumretuzumab, a humanized and glycoengineered anti-HER3 monoclonal antibody, in patients with advanced cancer.EXPERIMENTAL DESIGN: Twenty-five patients with histologically confirmed HER3-expressing tumors received lumretuzumab (100, 200, 400, 800, 1,600, and 2,000 mg) every two weeks (q2w) in 3+3 dose-escalation phase. In addition, 22 patients were enrolled into an extension cohort at 2,000 mg q2w.RESULTS: There were no dose-limiting toxicities. Common adverse events (any grade) included diarrhea (22 patients, 46.8%), fatigue (21 patients, 44.7%), decreased appetite (15 patients, 31.9%), infusion-related reactions (13 patients, 27.7%), and constipation (10 patients, 21.3%). The peak concentration (Cmax) and area under the concentration-time curve up to the last measurable concentration (AUClast) of lumretuzumab increased more than dose proportionally from 100 mg up to 400 mg. Linear PK was observed with doses ≥ 400 mg q2w indicating target-mediated drug disposition saturation. Downregulation of HER3 membranous protein was observed in on-treatment tumor biopsies from 200 mg, and was maximal at and above 400 mg. An ex vivo assay demonstrated increased activation potential of peripheral NK lymphocytes with lumretuzumab compared with a non-glycoengineered anti-HER3 antibody. Ten patients (21.3%) had stable disease and remained on study at a median of 111 days (range, 80-225 days).CONCLUSIONS: Lumretuzumab was well tolerated and showed evidence of clinical activity. Linear serum PK properties and plateauing of PD effects in serial tumor biopsies indicate optimal biologically active doses of lumretuzumab from 400 mg onwards.",

keywords = "Journal Article, Research Support, Non-U.S. Gov't",

author = "Didier Meulendijks and Wolfgang Jacob and Maria Martinez-Garcia and Alvaro Taus and Lolkema, {Martijn P} and Voest, {Emile E} and Langenberg, {Marlies H G} and {Fleitas Kanonnikoff}, Tania and Andres Cervantes and {De Jonge}, {Maja J} and Stefan Sleijfer and Morten Mau-S{\o}rensen and Marlene Thomas and Maurizio Ceppi and Georgina Meneses-Lorente and Ian James and Celine Adessi and Francesca Michielin and Keelara Abiraj and Birgit Bossenmaier and Schellens, {Jan H M} and Martin Weisser and Lassen, {Ulrik Niels}",

note = "{\textcopyright}2015 American Association for Cancer Research.",

year = "2016",

month = feb,

day = "15",

doi = "10.1158/1078-0432.ccr-15-1683",

language = "English",

volume = "22",

pages = "877--85",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research (A A C R)",

number = "4",

}

TY - JOUR

T1 - First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

AU - Meulendijks, Didier

AU - Jacob, Wolfgang

AU - Martinez-Garcia, Maria

AU - Taus, Alvaro

AU - Lolkema, Martijn P

AU - Voest, Emile E

AU - Langenberg, Marlies H G

AU - Fleitas Kanonnikoff, Tania

AU - Cervantes, Andres

AU - De Jonge, Maja J

AU - Sleijfer, Stefan

AU - Mau-Sørensen, Morten

AU - Thomas, Marlene

AU - Ceppi, Maurizio

AU - Meneses-Lorente, Georgina

AU - James, Ian

AU - Adessi, Celine

AU - Michielin, Francesca

AU - Abiraj, Keelara

AU - Bossenmaier, Birgit

AU - Schellens, Jan H M

AU - Weisser, Martin

AU - Lassen, Ulrik Niels

PY - 2016/2/15

Y1 - 2016/2/15

N2 - PURPOSE: A first-in-human phase I study was conducted to characterize safety, efficacy, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of lumretuzumab, a humanized and glycoengineered anti-HER3 monoclonal antibody, in patients with advanced cancer.EXPERIMENTAL DESIGN: Twenty-five patients with histologically confirmed HER3-expressing tumors received lumretuzumab (100, 200, 400, 800, 1,600, and 2,000 mg) every two weeks (q2w) in 3+3 dose-escalation phase. In addition, 22 patients were enrolled into an extension cohort at 2,000 mg q2w.RESULTS: There were no dose-limiting toxicities. Common adverse events (any grade) included diarrhea (22 patients, 46.8%), fatigue (21 patients, 44.7%), decreased appetite (15 patients, 31.9%), infusion-related reactions (13 patients, 27.7%), and constipation (10 patients, 21.3%). The peak concentration (Cmax) and area under the concentration-time curve up to the last measurable concentration (AUClast) of lumretuzumab increased more than dose proportionally from 100 mg up to 400 mg. Linear PK was observed with doses ≥ 400 mg q2w indicating target-mediated drug disposition saturation. Downregulation of HER3 membranous protein was observed in on-treatment tumor biopsies from 200 mg, and was maximal at and above 400 mg. An ex vivo assay demonstrated increased activation potential of peripheral NK lymphocytes with lumretuzumab compared with a non-glycoengineered anti-HER3 antibody. Ten patients (21.3%) had stable disease and remained on study at a median of 111 days (range, 80-225 days).CONCLUSIONS: Lumretuzumab was well tolerated and showed evidence of clinical activity. Linear serum PK properties and plateauing of PD effects in serial tumor biopsies indicate optimal biologically active doses of lumretuzumab from 400 mg onwards.

AB - PURPOSE: A first-in-human phase I study was conducted to characterize safety, efficacy, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of lumretuzumab, a humanized and glycoengineered anti-HER3 monoclonal antibody, in patients with advanced cancer.EXPERIMENTAL DESIGN: Twenty-five patients with histologically confirmed HER3-expressing tumors received lumretuzumab (100, 200, 400, 800, 1,600, and 2,000 mg) every two weeks (q2w) in 3+3 dose-escalation phase. In addition, 22 patients were enrolled into an extension cohort at 2,000 mg q2w.RESULTS: There were no dose-limiting toxicities. Common adverse events (any grade) included diarrhea (22 patients, 46.8%), fatigue (21 patients, 44.7%), decreased appetite (15 patients, 31.9%), infusion-related reactions (13 patients, 27.7%), and constipation (10 patients, 21.3%). The peak concentration (Cmax) and area under the concentration-time curve up to the last measurable concentration (AUClast) of lumretuzumab increased more than dose proportionally from 100 mg up to 400 mg. Linear PK was observed with doses ≥ 400 mg q2w indicating target-mediated drug disposition saturation. Downregulation of HER3 membranous protein was observed in on-treatment tumor biopsies from 200 mg, and was maximal at and above 400 mg. An ex vivo assay demonstrated increased activation potential of peripheral NK lymphocytes with lumretuzumab compared with a non-glycoengineered anti-HER3 antibody. Ten patients (21.3%) had stable disease and remained on study at a median of 111 days (range, 80-225 days).CONCLUSIONS: Lumretuzumab was well tolerated and showed evidence of clinical activity. Linear serum PK properties and plateauing of PD effects in serial tumor biopsies indicate optimal biologically active doses of lumretuzumab from 400 mg onwards.

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1158/1078-0432.ccr-15-1683

DO - 10.1158/1078-0432.ccr-15-1683

M3 - Journal article

C2 - 26463709

SN - 1078-0432

VL - 22

SP - 877

EP - 885

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 4

ER -

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this